News

• First clinical data to be reported for SAR566658, further expanding the extensive body of data reported with ImmunoGen's maytansinoid antibody-drug conjugate (ADC) technology.
• Presentations on new ADC technologies, including a new class of payload agents, highlight ImmunoGen's continuing leadership in advancing this high potential field.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, today announced the Company-related poster presentations accepted for the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting to be held October 19-23, 2013 in Boston, MA.

The first clinical data with SAR566658 are to be reported. This ADC is a potential new treatment for ovarian, pancreatic, breast and other CA6-positive cancers in development by Sanofi through a collaboration with the Company. Additionally, ImmunoGen scientists will report on the Company's new platform of DNA-acting cytotoxic agents for use in ADCs as well as on an additional linker ImmunoGen has added to its already extensive technology portfolio.

Poster Presentations

On Sunday, Oct. 20, the first SAR566658 clinical data are scheduled to be presented from 12:30-3:00 pm and 6:30-7:30 pm ET.

• "A phase I first-in-human study of SAR566658, an anti-CA-6-antibody-drug conjugate in patients with CA6-positive advanced solid tumors" (Poster Session A, Abstract #A73).

On Tuesday, Oct. 22, 12:30-3:00pm ET, three posters on ImmunoGen's expanding ADC technology portfolio are scheduled to be presented:

• "New Class of DNA-alkylating agents with a suitable tolerability profile created for use in antibody-drug conjugates (ADCs)" (Poster Session C, Abstract #C160).
• "Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models" (Poster Session C, Abstract #C162).
• "New tri-glycl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs)" (Poster Session C, Abstract #C164).

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells. The most advanced compound with ImmunoGen's ADC technology is Roche's Kadcyla^®, which is marketed in the US by Genentech and is also gaining approvals internationally. ImmunoGen has four wholly owned clinical-stage product candidates, with additional compounds in the clinic through its partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.

Kadcyla^® is a registered trademark of Genentech, Inc., a member of the Roche Group.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products and new anticancer technologies. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2013 and other reports filed with the Securities and Exchange Commission.

ImmunoGen, Inc.

Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
or
The Yates Network
Barbara Yates, 781-258-6153

Source: ImmunoGen, Inc.

News Provided by Acquire Media